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Background
Sarcomeric gene mutations are responsible for hyper-
trophic cardiomyopathy (HCM). In gene mutation carriers
without significant left ventricular (LV) hypertrophy (G
+LVH-), subtle abnormalities can exist as mitral valve
elongation, crypts, markers of elevated LV systolic func-
tion, and abnormal apical trabeculation. Reverse curvature
of the interventricular septum into the LV is a characteris-
tic of G+LVH+ patients. We aimed to assess LV septal
convexity into the LV in G+LVH-.
Methods
Cardiovascular magnetic resonance was performed on 36
G+LVH- individuals (31±14 years, 33% men) with a
pathogenic sarcomere mutation, and 36 sex and age-
matched healthy volunteers (33±12 years, 33% men). Sep-
tal convexity (SCx) was measured in the apical four cav-
ities view using a reference line joining the mid-septal wall
at tricuspid valve insertion level and the apical right ventri-
cular insertion. SCx was the maximal distance from this
line to the LV endocardium border (A-B). The Figure
depicts an example of SCx into LV in a G+LVH- (a) vs.
matched control (b).
Results
Mean septal convexity into LV was 5.0±2.5mm in G
+LVH- vs. 1.6±2.4mm in controls (p≤0.0001). Compared
to controls, G+LVH- individuals also had longer anterior
mitral valve leaflet (23.5±3.0mm vs. 19.9±3.1mm,
p≤0.0001), higher relative wall thickness (0.31±0.05 vs.
0.29±0.04, p≤0.05), higher ejection fraction (70.8±4.3% vs.
68.3±4.4%, p≤0.05), and smaller LV end-systolic volume
index (21.4±4.4ml/m2 vs. 23.7±5.8ml/m2, p≤0.05). Other
morphologic measurements of LV angles, sphericity index,
and excentricity index were not significantly different
between G+LVH- individuals and controls.
Conclusions
Septal convexity into LV is an additional feature of precli-
nical HCM, occurring before the presence of any
hypertrophy.
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